Bank of America’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-46
Closed -$256 – 6680
2025
Q4
$256 Buy
46
+19
+70% +$211 ﹤0.01% 6660
2025
Q3
$198 Buy
27
+5
+23% +$42 ﹤0.01% 7733
2025
Q2
$166 Buy
22
+4
+22% +$62 ﹤0.01% 7876
2025
Q1
$335 Buy
18
+2
+13% +$63 ﹤0.01% 7592
2024
Q4
$581 Buy
16
+5
+45% +$139 ﹤0.01% 7385
2024
Q3
$310 Sell
11
-186
-94% -$4.13K ﹤0.01% 7479
2024
Q2
$5.05K Sell
197
-899
-82% -$40.9K ﹤0.01% 7002
2024
Q1
$82.9K Buy
1,096
+347
+46% +$27.5K ﹤0.01% 6328
2023
Q4
$77.2K Buy
+749
New +$67.2K ﹤0.01% 6479
2023
Q3
– Sell
-10
Closed -$932 – 7664
2023
Q2
$1.13K Buy
+10
New +$1.27K ﹤0.01% 7226
2023
Q1
– Sell
-2
Closed -$175 – 7687
2022
Q4
$144 Buy
+2
New +$153 ﹤0.01% 7611
2022
Q3
– Hold
0
– – – 8142
2022
Q2
– Hold
0
– – – 8323
2022
Q1
– Hold
0
– – – 8685
2021
Q4
– Sell
-1,240
Closed -$88.4K – 8582
2021
Q3
$101K Buy
+1,240
New +$97.9K ﹤0.01% 6720
2020
Q2
– Sell
-16,550
Closed -$3.48M – 7090
2020
Q1
$3.48M Hold
16,550
– – ﹤0.01% 3020
2019
Q4
$3.47M Hold
16,550
– – ﹤0.01% 3569
2019
Q3
$3.43M Hold
16,550
– – ﹤0.01% 3571
2019
Q2
$3.38M Buy
+16,550
New +$3.37M ﹤0.01% 3594

Other funds holding RVPH

Bank of America's RVPH Position: Q1 2026 in Review

Bank of America sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q1 2026, closing a stake of 46 shares — an estimated $256 sold.

Bank of America first reported a position in RVPH in Q2 2019 and held it in 16 quarters. The position peaked at $3.48M in Q1 2020. 35 funds tracked by Wall St. Rank hold RVPH as of Q1 2026.

  • Bank of America reported no remaining REVIVA PHARMA HLDGS INC position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 46 REVIVA PHARMA HLDGS INC shares in Q1 2026, an estimated $256.
  • Bank of America first reported a position in REVIVA PHARMA HLDGS INC in Q2 2019 and held it in 16 quarters.
  • Bank of America's REVIVA PHARMA HLDGS INC position peaked at $3.48M in Q1 2020.
  • 35 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.